Starpharma Signs Cancer Drug Agreement with AstraZeneca

Starpharma Signs Cancer Drug Agreement with AstraZeneca

6 September 2012

Melbourne, Australia: Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY)  today announced the signing of an agreement with global pharmaceutical company AstraZeneca giving AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma's dendrimer technology.

Under the agreement AstraZeneca will undertake oncology studies using specific Starpharma drug-dendrimer conjugate molecules. The primary objective of the program is to assess the suitability of the dendrimer constructs for particular applications within the cancer field.

The identity of the anti-cancer molecules to be studied is covered by confidentiality restrictions, but Starpharma notes that the arrangement does not relate to docetaxel or to dendrimer conjugates of docetaxel. Further details of the arrangement between the parties were not disclosed.

For further information
Media:

Buchan Consulting
Rebecca Wilson

+61 417 382 391

[email protected]

Starpharma:
Dr Jackie Fairley

Chief Executive Officer

+61 3 8532 2704

Ben Rogers

Company Secretary

+61 3 8532 2702

[email protected]

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.